Technology | 2016.04.12
Gene-Editing Company Intellia Discloses IPO Plan, Regeneron Pact - Wall Street Journal
| STAT | Gene- Editing Company Intellia Discloses IPO Plan, Regeneron Pact Wall Street Journal Intellia Therapeutics Inc., a biotechnology company working on “ editing ” defective genes, has disclosed its plans for an initial public offering. The Cambridge, Mass., company is developing potential treatments for liver and blood diseases and cancer ... CRISPR company Intellia, which aims to treat disease with gene editing , files for $120 million IPO Gene editing biotech Intellia Therapeutics files for a $120 million IPO Regeneron inks deal to develop drugs using gene editing technology CRISPR/Cas9 |
For more information, please visit
http://news.google.com/news/url?sa=t&fd=[...]ntellia-discloses-ipo-plan-reg
Follow us on
Instagram is adding automatic in-app text translation - The Verge views: 1530
Here’s a ‘Brand-New’ Massive Multilingual Dataset for Machine Translation views: 1527